PRA Health Sciences (PRAH) Stock Rating Upgraded by BidaskClub

PRA Health Sciences (NASDAQ:PRAH) was upgraded by BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued to investors on Wednesday.

Other equities research analysts also recently issued research reports about the stock. SunTrust Banks reaffirmed a “buy” rating and issued a $101.00 target price on shares of PRA Health Sciences in a research note on Friday, October 27th. Zacks Investment Research downgraded shares of PRA Health Sciences from a “buy” rating to a “hold” rating in a research note on Thursday, September 7th. Mizuho began coverage on shares of PRA Health Sciences in a research note on Thursday, September 21st. They issued a “buy” rating and a $82.00 target price for the company. Credit Suisse Group upped their target price on shares of PRA Health Sciences from $90.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday, October 26th. Finally, Barclays began coverage on shares of PRA Health Sciences in a research note on Monday, December 11th. They issued an “overweight” rating and a $94.00 target price for the company. One investment analyst has rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $90.46.

PRA Health Sciences (NASDAQ:PRAH) opened at $91.14 on Wednesday. PRA Health Sciences has a twelve month low of $53.92 and a twelve month high of $92.00. The firm has a market cap of $5,800.23, a P/E ratio of 50.92, a P/E/G ratio of 1.58 and a beta of 0.40. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 1.38.

PRA Health Sciences (NASDAQ:PRAH) last announced its quarterly earnings data on Wednesday, October 25th. The medical research company reported $0.88 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.85 by $0.03. PRA Health Sciences had a net margin of 5.64% and a return on equity of 21.66%. The business had revenue of $494.55 million for the quarter, compared to analyst estimates of $477.89 million. During the same period in the prior year, the business posted $0.64 earnings per share. PRA Health Sciences’s revenue was up 23.7% compared to the same quarter last year. equities analysts predict that PRA Health Sciences will post 3.2 EPS for the current fiscal year.

In other news, Director Matthew P. Young sold 5,115 shares of the stock in a transaction on Thursday, November 16th. The shares were sold at an average price of $79.90, for a total transaction of $408,688.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 2.10% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of the company. Renaissance Group LLC boosted its holdings in PRA Health Sciences by 2.5% during the second quarter. Renaissance Group LLC now owns 5,239 shares of the medical research company’s stock worth $393,000 after purchasing an additional 126 shares during the last quarter. Los Angeles Capital Management & Equity Research Inc. boosted its holdings in PRA Health Sciences by 1.9% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 8,505 shares of the medical research company’s stock worth $638,000 after purchasing an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in PRA Health Sciences by 12.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after purchasing an additional 160 shares during the last quarter. Zacks Investment Management boosted its holdings in PRA Health Sciences by 1.3% during the second quarter. Zacks Investment Management now owns 48,885 shares of the medical research company’s stock worth $3,667,000 after purchasing an additional 614 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in PRA Health Sciences by 4.9% during the second quarter. Sei Investments Co. now owns 14,654 shares of the medical research company’s stock worth $1,100,000 after purchasing an additional 690 shares during the last quarter. 98.22% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “PRA Health Sciences (PRAH) Stock Rating Upgraded by BidaskClub” was first reported by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The legal version of this story can be read at https://www.com-unik.info/2017/12/27/pra-health-sciences-prah-stock-rating-upgraded-by-bidaskclub.html.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

What are top analysts saying about PRA Health Sciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for PRA Health Sciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit